Evaluating Patients With Abnormal Levels of Gastric Acid

Status Completed

Clinical Trial Summary

This study is used by the Digestive Diseases Branch to evaluate patients with suspected abnormalities in the secretion of gastric acid. The level of gastric acid is measured by analyzing the gastric juices of each individual patient. The gastric acid sample is obtained by a procedure known as nasogastric suctioning, where a thin plastic tube is passed from the nose to the stomach.

Depending on the patient's present condition further diagnostic testing may be required to achieve a diagnosis.

Clinical Trial Description

This study is an omnibus protocol used by the Digestive Diseases Branch to evaluate patients with suspected abnormalities of gastric acid secretion. Gastric acid secretion is measured by means of analysis of gastric juices obtained by nasogastric suction. Other clinically indicated diagnostic procedures are performed depending on the patient's clinical state in order to reach a diagnosis. ;

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00001240
Study type	Observational
Source	National Institutes of Health Clinical Center (CC)
Contact
Status	Completed
Phase	N/A
Start date	January 1989
Completion date	January 2004

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02108782` - Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors	Phase 2
Terminated	`NCT02273752` - Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer	Phase 2
Terminated	`NCT00084461` - Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors	Phase 2
Completed	`NCT00131911` - Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors	Phase 2
Recruiting	`NCT03583528` - DOTATOC PET/CT for Imaging NET Patients
Withdrawn	`NCT04915144` - 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs	Phase 2
Completed	`NCT00001191` - The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid	Phase 2
Completed	`NCT01525082` - Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors	Phase 2
Completed	`NCT00655655` - Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00075439` - Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors	Phase 2
Active, not recruiting	`NCT01824875` - Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors	Phase 2
Completed	`NCT00004074` - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu	Phase 1
Completed	`NCT02259725` - Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors	Phase 2
Terminated	`NCT02031536` - Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery	Phase 2